American Cyanamid's paclitaxel
Executive Summary
Hauser signs exclusive worldwide multiyear commercialization contract to supply bulk semi-synthetic paclitaxel, currently marketed in finished form as Bristol-Myers Squibb's Taxol, to American Cyanamid in return for an initial $1 mil. payment, the companies announce May 13. American Cyanamid subsidiary Immunex will develop and market paclitaxel for the U.S. and Canada, and Lederle will be responsible outside of North America. Cyanamid and Hauser also will collaborate in the research and development of new taxane analogs